Ofatumumab Monoclonal Antibody Affinity Maturation Through in silico Modeling

BACKGROUND: Ofatumumab, an anti-CD20 mAb, was approved in 2009 for the treatment of chronic lymphocytic leukemia. This mAb acts through immune-mediated mechanisms, in particular complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity by natural killer cells as well as antibody...

Descripción completa

Detalles Bibliográficos
Autores principales: Payandeh, Zahra, Rajabibazl, Masoumeh, Mortazavi, Yousef, Rahimpour, Azam, Taromchi, Amir Hossein
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Pasteur Institute 2018
Materias:
Full Length
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5889503/
https://www.ncbi.nlm.nih.gov/pubmed/28992681
http://dx.doi.org/10.22034/ibj.22.3.180

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5889503/
https://www.ncbi.nlm.nih.gov/pubmed/28992681
http://dx.doi.org/10.22034/ibj.22.3.180

Ejemplares similares